➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Merck
Baxter
McKesson
Express Scripts

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HUMULIN R PEN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Humulin R Pen

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00522210 ↗ Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes Completed University of Calgary N/A 2008-03-01 The purpose of this study is to determine whether there is a difference in blood sugar control (as measured by hemoglobin A1c (HA1c)), in children given twice daily insulin injections incorporating a new long acting insulin analogue (detemir) compared to children using their current three times a day insulin injections (with intermediate and rapid acting insulin).
NCT00532766 ↗ Evaluating Pharmacokinetics and Pharmacodynamics of Jusline Completed King Saud University N/A 2006-11-01 To evaluate the pharmacokinetic and pharmacodynamic profile of a new human insulin (Jusline) after subcutaneous administration, and to compare this profile with Humulin insulin.
NCT00646581 ↗ Effect of Single Dose Intranasal Insulin On Cognitive Function Completed University of Massachusetts, Worcester Phase 4 2006-10-01 The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's effect on cognition. The specific aims include: 1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on cognitive functioning, including attention and memory. 2. Examine whether single dose of intranasal insulin administration will raise serum insulin level and decrease plasma glucose level Insulin will be delivered through an air spray pump into your nose. The investigators will be comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.
NCT00657930 ↗ Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir┬« (Insulin Detemir) Completed Novo Nordisk A/S N/A 2008-03-01 This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard┬«, Humulin┬« N (NPH insulins) as basal insulin as part of their ICT under normal clinical practice conditions in Hungary.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Humulin R Pen

Condition Name

Condition Name for Humulin R Pen
Intervention Trials
Type 2 Diabetes Mellitus 5
Type 1 Diabetes Mellitus 3
Diabetes Mellitus, Type 2 3
Hyperglycemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Humulin R Pen
Intervention Trials
Diabetes Mellitus 17
Diabetes Mellitus, Type 2 10
Diabetes Mellitus, Type 1 6
Hyperglycemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Humulin R Pen

Trials by Country

Trials by Country for Humulin R Pen
Location Trials
United States 16
Italy 10
India 7
Canada 4
Russian Federation 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Humulin R Pen
Location Trials
California 5
Texas 3
Arizona 2
Utah 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Humulin R Pen

Clinical Trial Phase

Clinical Trial Phase for Humulin R Pen
Clinical Trial Phase Trials
Phase 4 6
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Humulin R Pen
Clinical Trial Phase Trials
Completed 18
Not yet recruiting 5
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Humulin R Pen

Sponsor Name

Sponsor Name for Humulin R Pen
Sponsor Trials
Halozyme Therapeutics 4
Biodel 2
Mayo Clinic 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Humulin R Pen
Sponsor Trials
Other 25
Industry 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
AstraZeneca
Colorcon
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.